ArticleActa neuropathologica2023
Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042-26042.
Open access · hybridAbstract read
In one paragraph
Article in Acta neuropathologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection.Neuro-oncology · 2025Guideline
- Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: Prospective phase 2 MARCIE trial.Neuro-oncology · 2024Trial
- Pulmonary Metastasis of Grade 1 Meningioma Mimicking a Carcinoid Tumor: A Case Report with FDG PET/CT, Ga-68 DOTATATE PET/CT, and Pathological Confirmation.World journal of nuclear medicine · 2026Article
- Tumor location and morphological MRI features in relation to combined 1p/22q deletion in meningioma.Discover oncology · 2026Article
- Multidisciplinary management of meningiomas in the era of precision oncology.Nature reviews. Clinical oncology · 2026Review
- Prognostic impact of radiotherapy timing in WHO grade 2 and 3 meningiomas utilizing an integrated molecular-morphologic classification.Journal of neuro-oncology · 2026Article
- Prognostic stratification of chordoid meningiomas: the role of chromosome 1p/22q Loss.Acta neuropathologica communications · 2026Article
- A microenvironment-determined risk continuum refines subtyping in meningioma and reveals determinants of machine learning-based tumor classification.Nature genetics · 2026Article
- Merlin immunohistochemistry is a reliable surrogate marker for NF2 gene alterations in meningioma.Histopathology · 2025Article
- Molecular insights into prognostic model for meningiomas treated with stereotactic radiosurgery: negative impacts of 1q gain on tumor control and survival.Acta neuropathologica communications · 2025Article
- Postoperative radiotherapy in subtotally resected recurrent WHO grade 1 meningiomas with intermediate-/high-risk molecular profiles.Neuro-oncology · 2025Article
- Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes.Neuro-oncology · 2025Article
- Meningioma: Novel Diagnostic and Therapeutic Approaches.Biomedicines · 2025Review
- Refining prognostic stratification of atypical meningiomas: significance of chromosome 1p deletion and brain invasion.Acta neuropathologica communications · 2025Article
- cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas.Neuro-oncology · 2025Review
- Malignant Transformation of Meningiomas.Journal of Cancer · 2025Review
- Radioligand therapies in meningioma: Evidence and future directions.Neuro-oncology · 2024Review
- Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.Neuro-oncology · 2024Review
- [A 34-gene expression biomarker to predict oncologic outcome and treatment response after radiotherapy in meningioma].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
- Loss over 5% of chromosome 1p is a clinically relevant and applicable cut-off for increased risk of recurrence in meningioma.Acta neuropathologica · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 6 countries.
Sybren L N MaasDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Philipp SieversDepartment of Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany.
Damien C WeberPaul Scherrer Institute, Villigen PSI, Switzerland.
Michael WellerDepartment of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
Martin J van den BentThe Brain Tumor Center, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.
Maximilian J MairDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Johan M KrosDepartment of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Fransesca CarparrottiHôpitaux Universitaires de Genève, Geneva, Switzerland.
Andreas von DeimlingDepartment of Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany.
Villà Freixa SalvadorICO Badalona, Hospital Germans Trias I Pujol (Institut Catala D'Oncologia), Catalonia, Spain.
Saskia Marguerite PeerdemanDepartment of Neurosurgery, Amsterdam UMC, Amsterdam, The Netherlands.
Jose Casas-MartinEORTC Head Quarters, Brussels, Belgium.
Thierry GorliaEORTC Head Quarters, Brussels, Belgium.
Felix SahmDepartment of Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany. Felix.Sahm@med.uni-heidelberg.de.ORCID 0000-0001-5441-1962
Matthias PreusserDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
German Cancer Research Center · DEErasmus MC Cancer Institute · NLEuropean Organisation for Research and Treatment of Cancer · BEMedical University of Vienna · ATUniversity of Zurich · CHAmsterdam University Medical Centers · NLHôpital Beau-Séjour · CHInstitut Català d'Oncologia · ESLeiden University Medical Center · NL
Funding
Else Kröner-Fresenius-Stiftung 2015_A_60Else Kröner-Fresenius-Stiftung 2017_EKES.24German Cancer Aid 70112956
Abstract
PubMed holds no abstract for this paper.
Indexed as
Meningeal NeoplasmsMeningiomaChromosome DeletionChromosomesChromosomes, Human, Pair 1DNA MethylationHumansPrognosisWorld Health Organization
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.